Product Name: JAK3 (977-984) pY980+pY981
Product Number: PE-04AVQ01
| Size: | $US |
Peptide Name: JAK3 (977-984) pY980+pY981
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. Y980+Y981 phosphorylation stimulate phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: DKD(pY)(pY)VVR
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Modifications Other: Phosphorylated
Storage Conditions: -20°C
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. Y980+Y981 phosphorylation stimulate phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: DKD(pY)(pY)VVR
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Modifications Other: Phosphorylated
Storage Conditions: -20°C
Scientific Background: JAK3 is a protein-tyrosine kinase of the TK group and JakA family. Phosphorylation at T8, Y904 and Y980 increases phosphotransferase activity. Phosphorylation at Y939 also increases phosphotransferase activity and induces interaction with STAT5A. Phosphorylation at Y785 induces interaction with SH2-B-beta. Phosphorylation at Y981 inhibits phosphotransferase activity. It is involved in cytokine receptor-mediated intracellular signal transduction, including activation of an oncoprotein, PI3K. JAK3 may be an oncoprotein (OP). JAK3 mutations were commonly found in juvenile myelomonocytic leukemia from whole-exome sequencing studies from 13 individuals. JAK3 were hypothesized to be involved in the progression rather than the initiation of leukemia, and patients with mutated JAK3 were associated with poorer clinical results. Mutations in this gene have been found in blood, mouth, and ovarian cancers.
© Kinexus Bioinformatics Corporation 2017